Drug Monitoring

The Panel 1 Urine Drug Screen detects multiple commonly abused drugs in urine using immunoassay screening at defined cutoff levels. This test provides an initial overview of recent substance exposure, making it useful in clinical, workplace, or monitoring settings. Screening results indicate potential presence of one or more drugs, serving as a broad first step in evaluating substance use.

The Panel 3 Urine Drug Screen detects multiple commonly abused drugs in urine using immunoassay technology at defined cutoff levels. Designed as an expanded screening tool, it provides an initial overview of substance exposure across a broader range of drugs than basic panels. Results indicate potential presence of one or more substances, supporting clinical, workplace, and monitoring needs.

The Panel 4 Urine Drug Screen detects multiple commonly abused drugs in urine using immunoassay analysis at preset cutoff levels. As a broader screening option, Panel 4 covers an expanded set of substances compared to baseline panels, helping clinicians, workplace programs, and monitoring services assess recent drug exposure. Results reveal possible presence of one or more drugs for further evaluation.

The Panel 5 Urine Drug Screen detects multiple commonly abused drugs in urine using immunoassay screening at established cutoff levels. As a standard 5-panel test, it covers core substances like amphetamines, opioids, cocaine, cannabis, and PCP to provide a foundational assessment of substance exposure in clinical, workplace, or monitoring contexts. Positive findings may indicate the presence of one or more drugs.

The Alcohol Urine Drug Test quantitatively measures ethyl glucuronide (EtG) and ethyl sulfate (EtS) levels in urine to assess recent alcohol intake. This precise quantitative analysis enables clinicians and monitoring programs to track consumption patterns over time, distinguish between trace exposure and significant use, and support reliable alcohol monitoring in clinical, treatment, or legal settings.

The Panel 1 Urine Drug Screen with Confirmation detects multiple commonly abused drugs in urine and verifies positive findings with advanced confirmatory testing. This two-step process improves accuracy by reducing the chance of false positives, making it valuable for clinical, workplace, or monitoring settings. The combination of broad screening and confirmation ensures reliable assessment of recent substance exposure.

The Panel 6 Urine Drug Screen with Confirmation detects multiple commonly abused drugs in urine via immunoassay screening and then validates positive findings with confirmatory testing. This two-step method enhances result reliability by reducing false positives, providing a trustworthy overview of substance exposure suited for clinical, monitoring, or workplace settings.

The Alcohol Urine Drug Screen with Confirmation detects and confirms the presence of ethyl glucuronide (EtG), a direct metabolite of alcohol, in urine samples. This test is designed to identify recent alcohol use and verify initial screening results with confirmatory analysis, providing reliable and accurate information for monitoring purposes in clinical, legal, and treatment settings.

The Amphetamines Urine Drug Test quantitatively measures the concentration of amphetamine and methamphetamine in urine using advanced laboratory methods. This quantitative analysis provides precise levels to support clinical monitoring, treatment programs, or medical evaluation. It offers more information than a basic screen by showing how much of these compounds are present.

The Amphetamines Urine Drug Screen detects the presence of amphetamine and related compounds in urine above defined cutoff levels. This screening test provides an initial assessment of recent amphetamine use and is commonly applied in workplace, treatment, and clinical monitoring contexts. Results indicate detection at or above threshold limits but are not confirmed by additional testing.

The Amphetamines Urine Drug Screen with Confirmation combines initial screening and confirmatory testing to detect and verify the presence of amphetamines in urine. This method delivers both sensitivity and specificity, ensuring positive results are validated. Ideal for clinical, legal, or monitoring settings, it supports reliable reporting of amphetamine use.

The Amphetamines Urine Drug Screen with Confirmation and D/L Isomers first screens for amphetamine compounds, then applies confirmatory testing that distinguishes D- and L-methamphetamine isomers. This test combines detection, verification, and isomer differentiation to offer more precise insight in clinical, legal, or monitoring settings.

The Amphetamines Urine Drug Test with D/L Isomers quantitatively measures levels of amphetamine and methamphetamine in urine while distinguishing D- and L-isomer forms. This enhanced test provides detailed insight into stereoisomer composition, supporting clinical or forensic monitoring with greater specificity and clarity in amphetamine use assessment.

The Barbiturates Urine Drug Test quantitatively measures concentrations of key barbiturate drugs (e.g. phenobarbital, pentobarbital) in urine using mass spectrometry. This definitive analysis supports therapeutic monitoring, compliance tracking, and safety evaluation by providing precise levels rather than just presence/absence of barbiturates.

The Barbiturates Urine Drug Screen detects the presence of barbiturate compounds in urine above established cutoff levels, using immunoassay methodology. This screening test is used in clinical, treatment, and monitoring settings to identify barbiturate use. A positive result indicates detection but does not include confirmatory testing, so results should be interpreted in context.

The Barbiturates Urine Drug Screen with Confirmation performs an initial immunoassay screening for barbiturates and then confirms positives using mass spectrometry. It verifies the presence of barbiturate drugs like phenobarbital, pentobarbital, secobarbital, and more. Designed for clinical, legal, or treatment monitoring, it delivers both detection and validation for greater confidence in results.

The Base Panel Urine Drug Screen with Confirmation combines an initial multi-drug immunoassay screen with confirmatory testing to validate positive findings. It detects common substances across multiple drug classes in urine, then uses advanced analysis to confirm the presence of specific analytes. This dual approach boosts accuracy and confidence in results for clinical or monitoring settings.

The Benzodiazepines Urine Drug Test quantitatively measures concentrations of benzodiazepine compounds in urine using advanced analytical methods. Designed for clinical monitoring and treatment programs, this test provides exact levels rather than a simple positive/negative. Results offer better insight into use patterns, dosing, and compliance over time.

The Benzodiazepines Urine Drug Screen detects the presence of benzodiazepine compounds in urine above established cutoff levels using immunoassay techniques. This screening test identifies recent use of medications like diazepam, alprazolam, or lorazepam in clinical, treatment, or monitoring settings. Positive results indicate detection at threshold levels but are not confirmed by additional testing.

The Benzodiazepines Urine Drug Screen with Confirmation performs an initial screening for benzodiazepine compounds in urine, followed by confirmatory testing to validate positive results. This process ensures reliable identification of drugs like diazepam, lorazepam, or alprazolam in clinical or monitoring settings, adding confidence and specificity to benzodiazepine detection.

The Buprenorphine and Naloxone Urine Drug Test quantitatively measures concentrations of buprenorphine, naloxone, and their metabolites in urine using precise analytical techniques. This test offers detailed insight into medication-assisted therapy adherence, distinguishing between metabolite levels over time and helping clinicians monitor dosage, compliance, and drug disposition in a reliable manner.

The Buprenorphine Urine Drug Screen detects the presence of buprenorphine and its metabolites in urine above established cutoff levels using immunoassay screening methods. This test is commonly used in treatment, clinical monitoring, and compliance settings to identify recent buprenorphine use. Positive results reflect detection, but do not include confirmatory testing.

The Buprenorphine and Naloxone Urine Drug Screen with Confirmation begins with a screening test for buprenorphine and its metabolites (including naloxone) in urine, then validates positive findings using confirmatory methods. This combined approach balances sensitivity and specificity, helping clinicians, treatment programs, or monitoring services to reliably verify medication-assisted therapy adherence.

The Carisoprodol Urine Drug Test quantitatively measures levels of carisoprodol metabolite(s) in urine using highly sensitive analytical methods. This test provides precise concentration values instead of mere detection, supporting clinical monitoring, compliance evaluation, and case review. Results help distinguish trace exposure from significant use in medical or treatment settings.